BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37428911)

  • 21. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
    Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
    Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2.
    Zhang L; Wang W; Li X; He S; Yao J; Wang X; Zhang D; Sun X
    Int J Oncol; 2016 Jun; 48(6):2425-34. PubMed ID: 27035278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4α on hepatocellular carcinoma.
    Jiang CF; Wen LZ; Yin C; Xu WP; Shi B; Zhang X; Xie WF
    Oncotarget; 2016 May; 7(19):27408-21. PubMed ID: 27050273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
    He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
    J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
    Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
    J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
    Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
    Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B.
    Lee HH; Kim D; Jung J; Kang H; Cho H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
    Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
    Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
    Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
    Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
    Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY
    Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
    Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
    Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
    Zhao X; Liu Y; Yu S
    Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.